PUBLIC COMPANY
save$BEAMBeam Therapeutics Inc.
$BEAM21.10+0.43%Cambridge, MA, USupdated 3h ago
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Preclinical4Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- —A Long-term Follow-up Study in Patients Who Received BEAM-101
- phase1This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
- phase2BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
- phase2A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
- phase2A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
🐶 Hiring Signal
Where Beam Therapeutics Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaHematology 3Metabolic 1
News
- Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s StarnaPfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.fiercebiotech · 1d ago
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 6d ago
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 9d ago
- Beam says base-edited sickle cell therapy succeeds in Phase 1/2 studyBeam Therapeutics announced Tuesday that its base-edited sickle cell therapy succeeded in a clinical trial, meaning a third one-time therapy for the disease may soon enter the market. In Beam’s Pha…endpoints · 9d ago
- Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell successBeam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA appl…biospace · 9d ago
- STAT+: GLP-1s are given an FDA warning for rare eye condition riskThe FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”stat · 9d ago
- Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdownGearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…fiercebiotech · 9d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 9d ago
- Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches reviewThe majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerat…biospace · 15d ago
- Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misledPioneering IVF technique to reduce the risk of children inheriting mitochondrial diseases is being marketed as a fertility procedure for older women, despite little evidence it works.stat · 17d ago
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that